Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930171 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2HPGDAKR1C3 | |
| SCHEMBL3666589 | 0.94 | LMNA (0.59) | ALDH1A1LMNAUSP2HPGDAKR1C3 | |
| SCHEMBL2728631 | 0.92 | LMNA (0.58) | ALDH1A1LMNAUSP2HPGDAKR1C3 | |
| SCHEMBL11142367 | 0.89 | ALDH1A1 (0.74) | ALDH1A1HPGDAKR1C3SMN1; SMN2NPC1 | |
| SCHEMBL18805067 | 0.88 | RAB9A (0.51) | ALDH1A1LMNAUSP2AKR1C3SMN1; SMN2 | |
| SCHEMBL12615119 | 0.88 | RAB9A (0.51) | ALDH1A1LMNAUSP2AKR1C3SMN1; SMN2 | |
| SCHEMBL78465 | 0.82 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDAKR1C3SMN1; SMN2 | |
| SCHEMBL1171241 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3SMN1; SMN2NPC1 | |
| SCHEMBL17080008 | 0.80 | LMNA (0.50) | ALDH1A1LMNAUSP2HPGDAKR1C3 | |
| SCHEMBL19356857 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | claimed |
| EP-0106988-A1 | Pharmacologically active lactam derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | claimed |
| WO-2023160638-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-08-31 | — | — | WO | disclosed |
| CN-115043768-A | Method for synthesizing N-aryl pyrrolidine-2-ketone by acid-promoted ring opening of cyclopropyl | 新乡市润宇新材料科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| CN-102015636-B | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2014-08-13 | — | — | CN | disclosed |
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| CN-102015636-A | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2011-04-13 | — | — | CN | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| EP-0106988-A1 | Pharmacologically active lactam derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4189495-A | TREATMENT OF NERVOUS AND PSYCHOSOMATIC DISORDERS | SYNTHELABO (FR) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | ALDH1A1 2066/4885LMNA 4520/4885USP2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.